Sunday 27 May 2012
Headlines
Did you find this story interesting? (0) (0)
24/01/2012 13:11:54
Merck enters partnership to develop vaccines
Merck Animal Health (known as MSD Animal Health outside the USA and Canada) today announces that it has signed an agreement with the Department of Medical Microbiology of the University Medical Center (UMC) Utrecht and the Faculty of Veterinary Medicine of Utrecht University to embark on the development of innovative vaccination strategies against bacterial udder infections (mastitis) in dairy cattle.
The project is titled "Evasion Molecules in Bovine Mastitis Vaccines" (EVAC) and its objective is to develop a series of vaccines against difficult to treat infections with certain bacteria known to cause bovine mastitis. Examples of such bacteria are Staphylococcus aureus, Streptococcus uberis and Escherichia coli. The EVAC project is part of the ALTANT (ALTernatives for ANTibiotics) program that is coordinated by Immuno Valley, a public-private research consortium. The program is funded by the Dutch Ministry of Economic Affairs, Agriculture & Innovation as well as by academic and industrial partners with the aim to generate knowledge and alternative tools that complement the available treatments to control infectious diseases in farm animals.
Dr. Paul Vermeij, senior project leader at Merck Animal Health’s Discovery & Technology Department in Boxmeer (the Netherlands) explains: "In the open innovation model as applied in the EVAC project, we are combining the veterinary vaccine expertise of Merck Animal Health with the knowledge on evasion molecules of the Department of Medical Microbiology at UMC Utrecht and the expertise on bovine immunology available at the Faculty of Veterinary Medicine at Utrecht University."
"The technologies developed within the ALTANT program may result in an efficacious vaccine against bovine mastitis. In combination with our current therapeutic tools, it can result in unprecedented possibilities to control the disease. In addition to improvement of animal welfare and economic advantages for the farmer, such a vaccine can also contribute to a responsible use of antibiotics," added Dr. Rene Aerts, vice-president Global Biologicals R&D at Merck Animal Health.
Development of vaccines against bovine mastitis has long been hampered due to the fact that the relevant pathogens are capable of producing so-called ’immune evasion molecules’ that block or interfere with important processes in the immune system of the cow. Similarly, evasion molecules also appear to interfere with the immune response that is provoked with vaccines. Therefore, despite the induction of high antibody levels, the clinical efficacy of most mastitis vaccines that have been developed so far has been poor.
In the EVAC project, evasion molecules have been identified and characterized, and subsequently recombinant versions of these proteins have been produced. Combinations of such evasion molecules will be added to traditional antigens in candidate vaccines. Vaccination is expected to raise neutralizing antibodies against immune evasion molecules in the animal. As a consequence, the evasion system of the bacteria is impaired and the antibodies are able to neutralize the mastitis-causing pathogens. The availability of effective vaccines in addition to the current therapeutic treatments would provide unprecedented possibilities for the control of the disease and contribute to ongoing efforts to reduce the use of antibiotics.
Mastitis is a major problem for the dairy industry, affecting animal health and causing significant economic loss to the farmer of up to € 300 per cow per year (early culling, reduced milk yield, treatment costs and discarded milk). Although treatment with antibiotics is a common part of mastitis management, it is often associated with high treatment costs and its irresponsible use is increasingly associated with the risk of developing antibiotic resistance.
 |
The project is titled "Evasion Molecules in Bovine Mastitis Vaccines" (EVAC) and its objective is to develop a series of vaccines against difficult to treat infections with certain bacteria known to cause bovine mastitis. Examples of such bacteria are Staphylococcus aureus, Streptococcus uberis and Escherichia coli. The EVAC project is part of the ALTANT (ALTernatives for ANTibiotics) program that is coordinated by Immuno Valley, a public-private research consortium. The program is funded by the Dutch Ministry of Economic Affairs, Agriculture & Innovation as well as by academic and industrial partners with the aim to generate knowledge and alternative tools that complement the available treatments to control infectious diseases in farm animals.
Dr. Paul Vermeij, senior project leader at Merck Animal Health’s Discovery & Technology Department in Boxmeer (the Netherlands) explains: "In the open innovation model as applied in the EVAC project, we are combining the veterinary vaccine expertise of Merck Animal Health with the knowledge on evasion molecules of the Department of Medical Microbiology at UMC Utrecht and the expertise on bovine immunology available at the Faculty of Veterinary Medicine at Utrecht University."
"The technologies developed within the ALTANT program may result in an efficacious vaccine against bovine mastitis. In combination with our current therapeutic tools, it can result in unprecedented possibilities to control the disease. In addition to improvement of animal welfare and economic advantages for the farmer, such a vaccine can also contribute to a responsible use of antibiotics," added Dr. Rene Aerts, vice-president Global Biologicals R&D at Merck Animal Health.
Development of vaccines against bovine mastitis has long been hampered due to the fact that the relevant pathogens are capable of producing so-called ’immune evasion molecules’ that block or interfere with important processes in the immune system of the cow. Similarly, evasion molecules also appear to interfere with the immune response that is provoked with vaccines. Therefore, despite the induction of high antibody levels, the clinical efficacy of most mastitis vaccines that have been developed so far has been poor.
In the EVAC project, evasion molecules have been identified and characterized, and subsequently recombinant versions of these proteins have been produced. Combinations of such evasion molecules will be added to traditional antigens in candidate vaccines. Vaccination is expected to raise neutralizing antibodies against immune evasion molecules in the animal. As a consequence, the evasion system of the bacteria is impaired and the antibodies are able to neutralize the mastitis-causing pathogens. The availability of effective vaccines in addition to the current therapeutic treatments would provide unprecedented possibilities for the control of the disease and contribute to ongoing efforts to reduce the use of antibiotics.
Mastitis is a major problem for the dairy industry, affecting animal health and causing significant economic loss to the farmer of up to € 300 per cow per year (early culling, reduced milk yield, treatment costs and discarded milk). Although treatment with antibiotics is a common part of mastitis management, it is often associated with high treatment costs and its irresponsible use is increasingly associated with the risk of developing antibiotic resistance.
|
Farming items for Sale
|
Claas 820CIS - Thame
(Price on Application)
(Price on Application)
John Deere 6930 - Ormskirk(GBP 46250)
CLAAS 816RZ TRACTOR - Chulmleigh
(Price on Application)
(Price on Application)
Case CVX170 - Maidstone(GBP 24900)
Case cs75 4wd, Chiltern loader - Telford(GBP 15450)
Related News
Land agents enter into partnership with FVSS - 15 May 2012A leading rural land and estate agent has joined into a partnership with Farm Valuation Services Scotland (FVSS). Bell Ingram has announced the ar...
Organic growth as partnership between Yeo Valley and The Cheese Company develops - 05 Nov 2007The Cheese Company and one of the biggest organic brands, Yeo Valley, have launched a new range of family sized packs of organic cheddar. The great ta...
PAVA develops partnership with a South-Korean bakery manufacturer - 21 May 2009Recently, a major Russian grain processor PAVA (www.apkhleb.ru) has announced its plans to further strengthen the export business and diversify the li...
Intervet’s bluetongue vaccine enters distribution chain - 01 May 2008The Veterinary Medicines Directorate (VMD) have granted Intervet the all clear to begin distributing its bluetongue vaccine, Bovilis® BTV8. The initia...
Japan-New Bird Flu vaccine developed. - 29 Jan 2009JAPAN-NEW BIRD FLU VACCINE. Researchers in Japan said Thursday they had developed a flu vaccine that works against multiple viruses and could preven...
Scientists take a step towards developing better vaccines for Bluetongue - 02 Aug 2011Researchers funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have taken a step towards producing better vaccines against B...
Merck and Sanofi to go separate ways in animal health business - 22 Mar 2011Merck and sanofi-aventis announced today the mutual termination of their agreement to form a new animal health joint venture by combining Merial, the ...
Merck Announces new name for its Animal Health Division - 29 Jun 2011Merck’s animal health division, formerly known as Intervet/Schering-Plough Animal Health, announced that effective today it will begin using the...
Merck Animal Health supports recovery of the Japanese animal sector - 10 Aug 2011Merck Animal Health (known as MSD Animal Health outside the USA and Canada), formerly known as Intervet/Schering-Plough Animal Health, announced today...
Farm products enter the new age; Bioscience leading to new partnerships - 22 Oct 2007Farming is entering the age of bioscience and that's good news for farmers and the environment, says Peter Hannam, president of Woodrill Farms nea...
